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ABSTRACT
Objective: Blood pressure(BP) and target organ responses to antihyperten-
sive drugs are not well established in hypertensive obese patients. This study 
is aimed at evaluating the effects of obesity and adiposity distribution pat-
terns on these responses. Methods: 49 hypertensive obese women were 
designated to different groups according to waist to hip ratio measurements 
– 37 with troncular and 12 with peripheral obesity. Patients were treated for 
24-weeks on a stepwise regimen with cilazapril alone or a cilazapril/hydro-
chlorothiazide/amlodipine combination therapy to achieve a BP lower than 
140/90mmHg. Ambulatory blood pressure monitoring (ABPM), echocardiog-
raphy, and albuminuria were assessed before and after the intervention. Re-
sults: After 24 weeks, weight loss was less than 2% in both groups. ABPM 
targets were achieved in 81.5% of patients upon a combination of 2(26.5%) or 
3(55.1%) drugs. Similar reductions in daytime-SBP/DBP: -22.5/-14.1(troncular 
obesity) / -23.6/-14.9mmHg (peripheral obesity) were obtained. Decrease in 
nocturnal-SBP was greater in troncular obesity patients. Upon BP control, 
microalbuminuria was markedly decreased, while only slight decrease in left 
ventricular mass was observed for both groups. Conclusions: In the absence 
of weight loss, most patients required combined antihypertensive therapy to 
control their BP, regardless of their body fat distribution pattern. Optimal tar-
get BP and normal albuminuria were achieved in the group as a whole and in 
both obese patient groups, while benefits to cardiac structure were of a small-
er magnitude. (Arq Bras Endocrinol Metab 2008;52/1:65-75)
Keywords: Hypertension; Obesity; Body fat distribution; Antihypertensive 
therapy; Echocardiography; Albuminuria.
RESUMO
Respostas Pressórica e Cardiorrenal à Terapia Anti-hipertensiva em 
Mulheres Obesas.
As respostas pressórica e de órgãos-alvo mediante o tratamento anti-hipertensi-
vo medicamentoso, não estão bem estabelecidas em pacientes obesos hiperten-
sos. O presente estudo tem por objetivo avaliar as repercussões da obesidade e 
da distribuição de gordura corporal sobre estas respostas. Métodos: Foram 
avaliadas 49 mulheres obesas hipertensas, separadas em subgrupos com dis-
tribuição troncular (n = 37) e periférica (n = 12) de gordura, de acordo com a 
distribuição cintura/quadril. As pacientes foram tratadas por 24 semanas com 
um regime anti-hipertensivo escalonado, iniciando-se com cilazapril e adicio-
nando-se na seqüência, hidroclortiazida e amlodipina, com alvo pressórico in-
ferior a 140 x 90 mmHg. Foram realizados MAPA, ecocardiograma e 
microalbuminuria antes e após o tratamento. Resultados: Depois de 24 sema-
nas observou-se perda de peso inferior a 2% em ambos os subgrupos. O con-
trole pressórico à MAPA pode ser observado em 81,5% das pacientes mediante 
a combinação de duas (26,5%) ou três (55,1%) drogas. Foram obtidas redu-
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Previous research from our group has previously dem-
onstrated the influence of obesity, and specifically visceral 
obesity, on the prevalence of hypertension, cardiovascular 
risk factors and target organ damage (3,9). Moreover, 
clinical data obtained from our outpatients showed the 
benefits of specific antihypertensive drugs and the inde-
pendent influence of weight reduction in terms of ade-
quate BP control in obese hypertensive patients (22,23).
In this study, we aimed at evaluating the influences 
of obesity, as well as fat distribution patterns, on blood 
pressure and target organ response upon pharmaco-
logical antihypertensive treatment.
PATIENTS AND METHODS
Subjects
Sixty-six hypertensive obese women (BMIt30kg/m2)
were enrolled in this study. Most of them were on anti-
hypertensive medication and, before the study entry, a 
washout period of 12 weeks was initiated for those on 
ACE-inhibitors and a minimum 4-week washout peri-
od for all other antihypertensive drugs.
BP was recorded in a sitting position using a mer-
cury sphygmomanometer. A 12-cm wide cuff was used 
and corrections for brachial circumference were made 
accordingly. Hypertension was defined as systolic blood 
pressure (SBP) t140 and/or diastolic blood pressure 
(DBP) t90mmHg for two consecutive readings one 
week apart, and the mean of the two readings was used. 
Over the washout period, 11 patients were exclud-
ed, mainly due to symptoms related to drug withdraw-
ções similares nas medidas de PAS/PAD diurnas: -22,5/-14,1(obesas troncula-
res)/-23,6/-14,9 mmHg (obesas periféricas), enquanto se observou nas obesas 
tronculares redução maior na PAS noturna. Mediante o controle pressórico, 
houve redução acentuada da microalbuminúria nos dois subgrupos. Por outro 
lado, observou-se em ambos, apenas discreta redução na massa ventricular. 
Conclusões: Na ausência de perda significativa de peso, e independentemen-
te da distribuição de gordura corporal, a maioria das pacientes obesas necessi-
tou terapia anti-hipertensiva combinada a fim de obter controle pressórico. Em 
ambos os subgrupos foram alcançados níveis adequados de pressão arterial e 
redução satisfatória da microalbuminúria, ao passo que os benefícios para a 
regressão estrutural cardíaca foram menores. (Arq Bras Endocrinol Metab 
2008;52/ 1:65-75)
Descritores: Hipertensão; Obesidade; Distribuição de gordura corporal; 
Terapia anti-hipertensiva; Ecocardiograma; Microalbuminúria.
INTRODUCTION
OBESITY IS A PREVALENT DISEASE in modern society and has a negative impact on health. Visceral obe-
sity has claimed more attention due to its association 
with cardiovascular risk (1), especially attributed to dia-
betes, dyslipidemia and hypertension (2, 3).
Indeed, available data show that neurohumoral, 
hemodynamic and inflammatory disorders, as well as 
target organ injuries in obese, are most commonly as-
sociated with visceral than with peripheral adiposity or 
total body fat (4-9).
Most studies that evaluate treatment of hyperten-
sion in obesity, as well as target organ responses, par-
ticularly the cardiorenal axis responses, regard weight 
loss, which has proven to be an effective approach 
(10-14). However, since weight loss maintenance is 
somewhat difficult, pharmacological antihypertensive 
therapy seems fundamental to keep BP under control 
and protect target organs (13).
Several pieces of evidence suggest that combina-
tion therapy is required in most obese hypertensive 
(15) and agents that block the renin-angiotensin sys-
tem may be especially beneficial (16-20). 
Nevertheless current guidelines do not provide 
specific recommendations for the treatment of hyper-
tension in obesity. In addition some therapeutic issues 
have not been assessed, such as the influence of obese 
patient heterogeneity (21), which may modulate blood 
pressure, metabolic disorders and target organ respons-
es to drugs differently.
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al; 55 patients entered the study protocol, 6 were 
eliminated because of drug related side effects (leg ede-
ma and cough) and 49 women with a body mass index 
(BMI) between 30.8 to 48.8kg/m2 were treated dur-
ing 24 weeks. Twenty-two patients (44.9%) had stage 1 
hypertension and the remaining ones were in stage 2.
Thirty-seven normotensive obese women, with a 
BMI between 30.4 and 50.0 kg/m2 and BP below 
140/90 mmHg, were selected for comparison with the 
hypertensive obese group.
Hypertensive and normotensive obese women were 
designated into groups according to the fat distribution, 
based on standard waist/hip ratio measurements (24).
Waist-to-hip ratio (WHR) has been largely used in 
population studies and shown to be a better predictive 
anthropometric parameter in assessing cardiovascular 
risk (25-28). Also, WHR has been proven to be better 
than waist circumference in its association with visceral 
fat measured by tomography in selected obese popula-
tions(29).
The classical cutoff value of 0.85 for WHR in wom-
en was not used in this study. Instead, a cutoff of 0.888 
derived from the first quartile of the mean for the hyper-
tensive obese group was used. As a result, normotensive 
and hypertensive groups were respectively divided into 
subgroups of 19 and 37 with troncular fat distribution 
(troncular obese subjects), and 18 and 12 with periph-
eral adiposity (peripheral obese subjects). 
This approach is warranted, since it has been dem-
onstrated a continuous and progressive risk according 
to increasing levels of WHR in groups of individuals 
with different body mass index levels, including those 
with BMI higher than 30kg/m2 (26). Moreover, the 
wide differences between South American, North 
American, European and Asian populations might in-
fluence the fat deposition pattern and therefore the 
classical cutoff value may not be the best choice. Re-
cently, a large worldwide population study, demon-
strated that the waist-to-hip ratio was highest in South 
American and Middle East American populations, when 
compared with other parts (27). 
Our approach is also supported by other studies 
which used higher anthropometrics threshold values 
(including WHR) for obese populations, determined 
from general population percentiles (30-32). 
Exclusion criteria 
Patients with SBPt180mmHg and/or DBPt110mmHg
prior to or during the washout period; BMIt50kg/m2;
diagnosis of secondary hypertension; diabetes; coro-
nary heart disease; heart and renal failure; and those 
who used drugs that might interfere with BP control, 
such as hormone replacement therapy, appetite sup-
pressants, anti-inflammatory agents, etc were excluded 
from the study.
This protocol met the requirements of the local 
Ethics Committee and all participants signed a written 
informed consent before being included.
Biochemical assessment
Serum glucose, insulin (immunoassay-micro particles, 
AXSYM-Abbott, normal range: 2.5-25.0 mU/l), nor-
epinephrine (high performance liquid chromatography, 
normal range: 144-352 pg/ml;) and microalbuminuria 
levels (in overnight urine; imunno-turbidimetry meth-
od – Cobas Mira Plus, Roche, normal values: <15 µg/
minute) were measured at the washout period and after 
24 weeks of treatment.
Echocardiographic Evaluation
Cardiac structure was evaluated by an M-mode/two-
dimensional echocardiogram (Esaote Biomedica – 
model SIM 5000). Septum thickness (SPT), posterior 
wall thickness (PWT) and left ventricular diastolic di-
ameter (LVDD) were obtained by ASE criteria. Left 
ventricular mass (LVM) was calculated according to 
Devereux formula (33) indexed by the exponential 
height (h2.7) (normal < 46.7g/m2.7), as proposed for 
obese individuals (34). 
24-hour ABPM
Twenty-four hour ambulatory blood pressure monitor-
ing (ABPM) was performed using a noninvasive auto-
matic monitor (Space Labs, model 90207). Daytime 
was considered as the period over which subjects were 
awake and went about their usual activities; nighttime 
was sleeping time. BP was read at 15- and 20-minute 
intervals all over day and night times. Mean daytime 
and nocturnal SBP and DBP were used in the analysis.
Antihypertensive treatment
To achieve BP targets of SBP<140mmHg and DBP< 
90mmHg in the 24-week follow-up period, patients en-
tered a stepwise antihypertensive drug regimen with up-
titration every 4 weeks, starting with the ACE inhibitor 
cilazapril, in doses ranging from 2.5mg to 5.0mg daily. 
Where BP targets were not achieved, of hydrochlorothi-
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azide (HCTZ) 12.5mg were added to the regimen and 
finally, as needed, 5 to10 mg amlodipine was given daily. 
Patients were evaluated on a monthly basis by BP 
readings and assessed for required adjustments to treat-
ment. Final drug regimens were evaluated as was the mean 
of individual drug doses taken during the 24 weeks.
All patients were recommended dietary changes 
and no pharmacological therapy for weight reduction 
was allowed.
Statistical Analysis
Data was stored in Excel software and analyzed by Jan-
del Scientific/ Sigma Stat and SPSS 8.0 programs. 
Mean ± 1 SD was used for continuous variables and 
median for microalbuminuria. Comparative analysis 
between groups was performed using Student’s t test 
and ANOVA. For non-continuous variables, Mann-
Whitney and Kruskal-Wallis tests were used. Covari-
ance test was used for age and BMI adjustments in 
comparisons between hypertensive and normotensive 
patients. Pre- and post-treatment analyses were per-
formed using paired t test and compared in terms of per-
centage differences by Student’s t test (95%CI). Variance 
analysis for repeated measurements reinforced those pre-
vious analyses. The random effects model was used to 
evaluate the association between blood pressure changes 
and antihypertensive agent in selected responses. P-values 
lower than 0.05 were considered significant.
RESULTS
Normotensive and hypertensive obese 
subjects
Normotensive and hypertensive obese groups differed 
significantly in age (39.8±11.6 vs 46.6±10.4 vs, p< 0.05) 
and BMI (39.3±9.0 vs 35.8±4.7 kg/m2, p<0.05). As ex-
pected, BP parameters and cardiorenal involvement were 
significantly higher in the hypertensive obese subjects 
after adjustments for these variables (Table 1).
Table 1. Office-BP, ABPM and target organ variables in hypertensive obese subjcets before and after treatment and in 
normotensive obese subjects.
Normotensive 
obese Hypertensive obese
Baseline 24 week %; baseline - 24 w
N 36 49 49
BMI (kg/m2) 39,3 r 9,0 35,8 r 4,7**1 35,2 r 4,7&1&2 -1,4 r 4,1
O-SBP (mmHg) 122,1 r 9,4 155,7 r 13,4*1 132,7 r 12,2*1*2 -23,2 r 14,5
O-DBP (mmHg) 78,5 r 6,1 99,5 r 7,0*1 84,9 r 10,1*1*2 -14,6 r 10,5
SBP-day (mmHg) 122,0 r 7,6 154,1 r 16,1*1 131,8 r 8,1*1*2 -22,8 r 15,8
DBP-day (mmHg) 76,2 r 7,2 98,9 r 11,8*1 84,6 r 7,2*1*2 -14,5 r 15,7
SBP-night (mmHg) 107,9 r 7,4 138,3 r 17,6*1 121,7 r 12,7*1*2 -17,0 r 14,1
DBP-night (mmHg) 62,0 r 6,3 83,7 r 12,3*1 72,9 r 8,1*1*2 -10,9 r 10,4
Plasma glucose (mg/dl) 91,8 r 14,7 100,8 r 10,6 99,0 r 14,4**1 -1,98 r 3,1
Cholesterol (mg/dl) 201,2 r35,6 220,5 r 42,2**1 215,1 r 48,5 -4,0 r 21,2
Insulin (mUI/ml) 16,4 r 9,5  15,0 r 6,3 18,4 r 7,5 3,4 r 1,8
Norepinephrine (pg/ml) 126,2 r65,5 150,4 r 78,9 180,9 r 63,6&1 30,5 r 17,0
LVM (g) 135,5 r26,9 175,3 r 39,7*1 161,2 r 36,0*1&2 -7,5 r 17,1
LVM/h 2,7 (g/m2,7) 40,4 r 7,0 53,6 r 12,6*1 49,7 r 11,3*1&2 -5,2 r 18,5
SPT (mm) 8,9 r 1,2 10,9 r 1,9*1 10,8 r 1,8*1 -0,6 r 16,6
PWT (mm) 9,0 r 1,3 10,8 r 1,7*1 10,2 r 1,6*1**2 -4,0 r 13,7
LVDD (mm) 46,2 r 4,3 45,3 r 3,9 44,4 r 4,1 -1,6 r 7,5
Micro (mcg/min) 6,4(1,9/37,4) 35,9 (7,6/68,1)**1 8,7 (4,5/20,3)*2 -64,3 (-88,9/-25,9)
O= office /SBP/DBP; LVM= left ventricular mass; LVM/h 2,7= corrected for height2,7; SPT=septum; PWT= posterior wall 
thickness; LVDD= left ventricular diastolic diameter; * p < 0,0001; & p < 0,01; ** p < 0,05; p-1vs obese normotensive subjects 
and p-2 vs obese hypertensive subjective at baseline.
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Table 2. Baseline characteristics of normotensive (n=37) and hypertensive obese (n=49) with relation to body fat distribution.
Normotensive obese Hypertensive obese
Peripheral
(N=18)
Troncular
(N=19)
Peripheral
(N=12)
Troncular
(N=37)
Age (years) 41.4 r 10.9 38.3 r 12.4 46.7 r 9.3 46.6 r 10.8 
Weight (kg) 90.7 r 15.5 94.5 r 12.1 87.9 r 19.6 85.8 r 11.5
BMI (kg/m2) 38,9 r 5.9 37.4 r 4.7 36.2 r 6.1 35.7 r 4.2
Waist/Hip Ratio 0.85 r 0.02 0.95 r 0.05* 0.85 r 0.03 0.96 r 0.05*
O-SBP (mmHg) 120.3 r 10.1 124.5 r 9.8 155.5 r 15.2 156.4 r 13.3
O-DBP (mmHg) 77.9 r 6.4 80.2 r 6.4 99.9 r 7.1 99.6 r 7.1
SBP-day (mmHg) 120.8 r 8.2 122.9 r 6.9 151.6 r 14.0 155.0 r 17.5
DBP-day (mmHg) 76.2 r 5.7 76.3 r 8.3 94.9 r 9.5 100.2 r 12.3
SBP-night (mmHg) 106.5 r 5.8 109.3 r 8.5 132.1 r 14.7 140.3 r 18.2
DBP-night (mmHg) 61.5 r 5.1 62.6 r 7.3 83.7 r 12.3 85.5 r 12.8
LVM/h2.7 (g/m2.7) 40.6 r 7.8 40.2 r 6.4 50.2 r 5.6 54.7 r 14.1
Microalbuminuria (µg/min) 3.2 (1.8 / 29.7) 10.7 (4.6 / 43.1)  15 (7.6 / 66.6) 36(6.1 / 96.1)
BMI= body mass index; O= office /SBP/DBP; LVM/h2,7= left ventricular mass corrected for height 2,7; p values are given for 
comparison between troncular and peripheral obesity.
* p<0,001.
Table 2 shows baseline demographic and clinical 
characteristics for each subgroup of normotensive and 
hypertensive patients. The subgroup analysis shows, as 
expected, significant differences in WHR. Despite non-
significant differences of BP and cardiorenal parameters 
between the subgroups, a trend toward higher BP lev-
els and cardiorenal impairment from peripheral normo-
tensive obese to troncular hypertensive obese subjects 
was observed.
Non-significant absolute higher values for noctur-
nal BP levels and a smaller nocturnal SBP dipping 
(p<0.05) were noted in troncular hypertensive obese 
subjects. This nocturnal BP pattern might have influ-
enced the heart structure, since inverse correlations of 
nocturnal SBP dipping with septum thickness (r2-0.30,
p<0.04), left ventricular wall thickness (r2-0.29, p<0.04) 
and left ventricular mass/height 2,7 (r2 –0.33, p < 0.03) 
were noted in hypertensive obese subjects.
In addition, in multiple regression analyses, target 
organ parameters were predicted by nocturnal SBP 
(septum and LV wall thickness, p <0.0001, coefficient 
0.05+ 0.01) and by nocturnal DBP (microalbuminuria, 
p< 0.01; coefficient 20.9+ 8.0).
Antihypertensive regimens
At the end of the 24th week 9 patients were still on 
cilazapril alone (18.4%), 13 were receiving cilazapril 
plus HCTZ (26.5%) and, for the remaining 27 patients 
(55.1%), the triple therapy with cilazapril plus HCTZ 
plus amlodipine was required.
Drug regimens were not significantly different be-
tween the troncular and peripheral hypertensive obese 
women: cilazapril alone (16.2% vs 25%); cilazapril 
+HCTZ (27% vs 25%) and cilazapril + HCTZ + amlo-
dipine (56.7% vs 50%), nor were the mean of daily dos-
es at the 24th week: cilazapril: 4.9±0.41 vs 5.0±0 mg/
day; HCTZ: 12.5±0 vs 12.5±0 mg/day and amlo-
dipine: 7.9±2.5 vs 8.3±2.6mg/day. Antihypertensive 
treatment was generally well tolerated and the drug-
related adverse side effect profile did not differ from 
that previously described for these medications.
Office blood pressure and ABPM responses 
to antihypertensive treatment 
Upon 24 weeks of antihypertensive therapy, hyperten-
sive obese subjects had their BP levels well controlled 
for both office and ABPM measurements, although fi-
nal levels were still higher than those found in normo-
tensive obese subjcets (Table 1).
Over ABPM daytime-SBP/DBP <135/85mmHg 
was observed in 24 HTOB patients (40.8%) and in a 
further 13 patients (26.5%), levels were lower than 
140/90mmHg. Ten patients had their final BP moni-
tored between 140-149 and 90-99 mmHg and in 7 
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ty) had a weight loss greater than 5%. BP responses in 
these patients were somewhat greater, although non-
significant, when measured in the office but not over 
ABPM. Also, changes in LVM/height2.7 did not differ 
from that observed in patients with weight loss < 5%.
Biochemical parameters
Baseline plasma glucose and insulin levels were similar 
in both obese hypertensive subgroups and did not 
change significantly during antihypertensive treatment 
(Table 1). Baseline plasma norepinephrine levels were also 
similar, increasing significantly during antihypertensive 
treatment in both obese subgroups, and that was probably 
related to the use of a calcium channel blocker, but they 
still remained within the normal range.
No significant correlations of those biochemical 
parameters were found for either BP or target organ 
damage at baseline or during treatment. 
Target organ responses
After 24 weeks, there was a slight decrease in LVM in 
the hypertensive obese group (p<0.01; -7.5±17.1%) 
Table 3. Office-BP, ABPM and target organ variables in hypertensive obese subjects with relation to fat distribution, before and 
after treatment. 
Blood pressure parameters
Troncular obesity Peripheral obesity
Washout 24 weeks Washout 24 weeks
N 37 37 12 12
O-SBP (mmHg) 156.4±13.3 133.4±13.3* 155.5±15.2 131.5±7.7*
O-DBP (mmHg) 99.6±7.1 85.5±10.9& 99.9±7.1 83.8±6.9 *
SBP-day (mmHg) 155.4 r 17.6 132.9 r 8.2 151.6 r 14.0 128.0 r 7.1*
DBP-day (mmHg) 100.4 r 12.5 83.0 r 6.5 94.9 r 9.5 80.0 r 7.6
SBP-night (mmHg) 140.7 r 18.3 121.4 r 13.2 132.1 r 14.7 121.7 r 11.8
DBP-night (mmHg) 85.5 r 13.0 73.3 r 8.5 78.5 r 9.4 71.3 r 6.8&
Ecocardiographic parameters
LVM (g) 178.6 r 93.7 165.8 r 39.5 165.1 r 22.3 153.7 r 20.1
LVM/h2.7 (g/m2.7) 54.7 r 14.1 50.7 r 12.3** 50.2 r 5.6 46.9 r 7.1
SPT (mm) 11.1 r 2.1 11.1 r 1.9 10.5 r 1.4 10.0 r 1.1
PWT (mm) 10.9 r 1.8 10.3 r 1.7** 10.2 r 0.97 9.4 r 1.2
LVDD (mm) 45.3 r 4.2 44.5 r 4.3 45.7 r 3.0 44.8 r 3.4
Renal parameter
Microlbuminuria (mcg/min) 36.5(6.1/ 96.1) 9.4 (5.1 /45.1)* 15.0(7.6/66.8) 7.7(38 / 14.1)&
O= office /SBP/DBP; LVM= left ventricular mass; LVM/h 2,7= corrected for height 2,7; SPT= septum; PWT= posterior wall thickness; 
LVDD= left ventricular diastolic diameter. 
p values are given for paired T test between baseline and 24-week treatment periods in hypertensive subgroups; * p < 0,001; 
& p < 0,01; ** p < 0,05.
(14.2%) the BP decrease was greater than 10%. Only 2 
patients had their final BP recorded higher than 
150/100mmHg.
Office BP and daytime/nocturnal ABPM values 
were similarly lower in both hypertensive obese sub-
groups after treatment (Table 3). However, greater de-
creases in night-time pressure, mainly for SBP 
(-19.3±14.3 vs -10.4±11.5mmHg, p<0.05), were ob-
served in the troncular hypertensive obese subjects. 
These findings were confirmed after performing vari-
ance analysis using repeated measurements (Figure 1). 
Despite BP target has been achieved in both hyperten-
sive obese subgroups (SBP: 130-135 and DBP: 
80-85mmHg), the differences against normotensive 
subgroups persisted, particularly for nocturnal values.
Body weight changes
Despite dietary recommendations (1200 to 1600 kcal/
day), there was only a slight body weight loss in most 
patients (Table 1), corresponding to less than 2% BMI 
reduction in both subgroups (troncular obese subjects: 
-1.4±4.3 %; peripheral obese subjects: -1.3±3.6%). Ten 
patients (8 with troncular and 2 with peripheral obesi-
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and post-treatment values were still significantly higher 
than in normotensive obese patients (Table 4).
Upon subgroup analysis (Table 3), a slight and similar 
decrease of LVM/ LVM/h2.7 was observed again for both 
troncular: -7.4%/-5.0% and peripheral: -8.0/-5.8% obese 
subjects, mainly due to PWT reduction. LVM/h2.7 values, 
especially for the troncular obese women, remained high-
er than the cutoff value for obese subjects (46.7g/m2.7)
and also significantly higher than what was seen for nor-
motensive obese subjects (Figure 2- Panel A).
Microalbuminuria, on the other hand, decreased 
significantly in the group as a whole (p<0.0001; -64.3%) 
and post-treatment levels were almost similar to those 
of normotensive obese subjects (Table 1). In both sub-
groups, UAE was greatly and similarly reduced and 
post-treatment levels also matched those for normo-
tensive subjects (Table 3; Figure 2- Panel B).
Both cardiac structural parameters and UAE changes 
occurred parallel to the drug dosages and consequent BP 
reductions. Therefore, as for cilazapril, cilazapril + hydro-
chlorothiazide and cilazapril + hydrochlorothiazide + am-
lodipine, reductions in BP were, respectively, daytime: 
-10.4±6.9/-6.8±4.7; -15.5±9.4/-9.1±6.0; -31.0±16.1/ 
-20.2±11.6mmHg; night-time: -1.2±8.2/-0.62±7.6; 
-16.8±9.5/-11.2±7.3; -22.7±14.3/-14.4±10.8 mmHg, 
which were accompanied by proportional changes in 
LVM/h2.7: -1.23±26.3; -4.9±13.7; -6.8±18.2 % and 
UAE: -37.2[-15/-87.9]; -52.0[-22.3/-85.8]; -58.8
[-25.9/-88.7]µg/min. WHR was similar among the three 
drug groups, which reinforces the independence between 
body fat distribution and antihypertensive demands.
Figure 2. Left ventricular mass indexed to 2,7(A) and 
microalbuminuria (B) in normotensive and hypertensive 
obese individuals; p- 1 vs peripheral and p-2 vs troncular 
normotensive obese individuals; p * <0.0001; & p <0.01; ** 
p <0.05; in the bars- between washout and 24 weeks 
-
Table 4 shows the results of random effects analysis, 
which evaluated the impact of BP variables and drugs on 
echocardiography and microalbuminuria changes. Both 
selection methods (forward or backward) showed that 
changes in LVM parameters were directly associated with 
nocturnal BP reduction, BMI and cilazapril doses. The 
change in microalbuminuria was associated with daytime 
SBP changes. These findings were confirmed when cen-
tral obese hypertensive subjects were separately analyzed. 
DISCUSSION
Failure to control blood pressure in obesity is usually 
attributed to persistent overweight and to the neu-
rohumoral-activated mechanisms (2,10,35), particularly 
in patients with troncular obesity who are in general 
more insulin resistant than those with peripheral obesity. 
Therefore greater difficulties to control blood pressure 
and more antihypertensive agent requirements might be 
antecipated for patients with troncular obesity. 
However, our data does not favor this assumption, 
since we observed a similar degree of decreased blood 
pressure using similar amounts of antihypertensive 
Figure1. Nocturnal systolic and diastolic blood pressures 
changes after 24-week therapy in obese subgroups; p time 
values are given between washout and 24-week period; p 
fall values are given between troncular and peripheral 
obesity subgroups. 
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medications in both troncular and peripheral obese hy-
pertensive women in 24 weeks of follow-up. Moreover, 
the troncular obese patients experienced a more signifi-
cant decrease in their nocturnal pressures. 
Therefore, our findings showed that antihyperten-
sive therapy was effective in providing a satisfactory BP 
control regardless of adiposity distribution.
It should be emphasized that both groups did not 
present a significant weight loss which would be of some 
benefit to BP or neurohumoral control (10,36). Weight 
maintenance and the supposed non-mobilization of vis-
ceral adiposity may even explain differences in pressure 
levels between treated HTOB and NTOB controls. In 
spite of similar W/H means between each subgroup 
(troncular and peripheral obesity) of normotensive and 
hypertensive obese subjects, it is likely that HTOB pres-
ent a greater accumulation of visceral adiposity that 
could be best detected by more accurate methods.
Some data point to visceral adiposity mobilization 
rather than weight loss as implicated in pressure and met-
abolic improvement in obese people (36). However, re-
fractoriness towards weight loss renders the adiposity 
mobilization little realistic, especially in women (37), thus 
strengthening maximization of antihypertensive therapy.
In this aspect, it is important to note that in order 
to reach the blood pressure target, the majority of pa-
tients needed treatment with 2 or 3 drugs and mono-
therapy was effective for only 18.4%. Mean number of 
medications per patient in our study was 2.4, and it was 
similar between women with troncular or peripheral 
obesity. These observations add to those in several clini-
cal trials on hypertension, which have shown the require-
ment of 2 or more antihypertensive agents to obtain an 
optimal BP control, particularly in high risk groups 
(38-40) and in more recent data from obese-hyperten-
sive populations (15), stressing the similarity of antihyper-
tensive requirements in obesity, a condition commonly 
linked to antihypertensive therapeutic failure (15,40), to 
that of high risk patients.
The drug regimen chosen for this study was based 
in part on the obesity-hypertension pathophysiology, 
where the advantages of the renin-angiotensin system 
blockade have been shown, (8,16,19,20,41) and also 
because it has been widely demonstrated that ACE-in-
hibitor, diuretic and calcium channel blocker combina-
tions adds efficacy to treatment and thus help to reach 
the BP targets.
Despite the antihypertensive efficacy, benefits to 
cardiac structural changes were far less than we expect-
ed. The reduction in LVM was on average only 14g 
(7.5%) and, after correction, LVM was still above the 
cutoff (46.7g/m2.7) (34). Similar observations were 
made for troncular and peripheral obese people, who 
respectively presented decreases in LVM of 7.5% and 
8.6%, reaching final means of 50.7 and 46.9 g/m2.7.
Since in this study most of the required conditions 
that contribute to LVM regression in the hypertensive 
Table 4. Random effects model for drug and blood pressure parameters with relation to echocardiography 
and albuminuria.
LVM/h2,71-2 Microalbuminuria(log)1-2
Selection Backward Backward/Forward
Coefficient p Coefficient p
Cilazapril -0.03 r 0.017 0.05 ---
Amlodipine 0.01 r 0.004 0.02 ---
HCTZ --- ---
SBP-day1-2 --- 0.03 r 0.007 < 0.0001
SBP-night1-2 --- ---
DBP-night1-2 0.30 r 0.08 0.0008 ---
BMI1-2 0.65 r 0.28 0.02 ---
Selection Forward
SBP-night1-2 0.24 r 0.05 < 0.0001
BMI1-2 0.59 r 0.28 0.04
LVM/h 2,7= left ventricular mass corrected for height2,7; HCTZ= hydroclorthiazide; 1-2= washout - 24 weeks 
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were present (42), e.g., appropriate decrease in BP, 
length of treatment, type of antihypertensive agents 
and previous left ventricular hypertrophy, it is reason-
able to suppose that the absence of a significant de-
crease in body weight, which is an important goal for 
cardiac reversion (11,12), was responsible for the main-
tenance of increased LVM. 
In MacMahon’s study, considerable weight reduc-
tion explained 25% of LVM variation (11). More re-
cently, Himeno (12), evaluating normotensive and 
hypertensive obese individuals with moderate weight 
losses, observed decreases in LVM of 9 and 12% with-
out BP decrease in normotensives.
Another study (43) compared two regimens in hy-
pertensive obese subjects, amlodipine with and without 
diet intervention, showed LVM decrease of 23.2% and 
14.7%, respectively. The 8.5% difference was apparently 
due to a 10% weight loss. Similarresults were obtained 
using captopril with and without diet intervention (44).
Previous data from our group and others (45, 46) 
also stressed the benefits of weight reduction upon 
pharmacologic therapy on LVM regression in obese 
hypertensive patients, regardless of BP control.
This data shows that about 10% of LVM decrease 
could have been added if a moderate weight loss had 
been achieved in this study.
It is clear that antihypertensive therapy alone is not 
able to properly reverse LVM in obese patients. Even 
with 2 to 3 drugs, no more than 10% decrease was ob-
tained. In the group with monotherapy, practically no 
LVM reversion was noted, coincidently with lack of 
nocturnal pressure dip, which was predictive of rever-
sion cardiac mass in this study.
Considering the obese subgroups, there were no 
differences in cardiac structural changes, BP control, 
drug intake and treatment length, as well as in weight 
loss. However, since troncular obese women had some-
what higher BP and LVM levels at baseline and experi-
enced greater nocturnal dips in pressures, a greater 
LVM decrease should therefore be expected in those 
patients. This was not the case, which might be due to 
maintenance of visceral adiposity in this subgroup.
Also, at 24 weeks, LVM remained greater than in 
normotensive obese subgroups. The persistence of an 
unestimated visceral adiposity accumulation in treated 
hypertensive obese subjects in this study, as well as 
higher, although controlled, BP levels, could also ex-
plain cardiac differences between treated patients and 
normotensive obese subjects. This observation is in 
keeping with an early trial, likewise studying treated 
and controlled hypertensive patients, which has shown, 
after 2.9 years, similar LVM differences when com-
pared to normotensive controls (47).
Although we were unable to demonstrate any cor-
relations of measured biochemical parameters in our 
study, this data strengthens the participation of non-
hemodynamic mechanisms (norepinephrine, leptin, in-
sulin, etc) in left ventricular hypertrophy of obese 
hypertensive patients, particularly in the troncular 
obese subgroup, and is in accordance with recently 
published data that demonstrates and independent as-
sociation of metabolic syndrome, expression of visceral 
fat (48) and LVM structure changes (49).
The impact of BP control on kidney damage was 
very successful in our treated hypertensive obese wom-
en, who had their microalbuminuria normalized and 
matching normotensive subjects. This data concurs 
with a previous study (50), in which microalbuminuria 
reduction occurred parallel to the degree of BP reduc-
tion and was particularly influenced by daytime SBP. 
Therefore, in contrast to the cardiac repercussions, 
proper blood pressure control overcame the eventual 
harmful renal consequences of weight maintenance in 
obese hypertensive individuals (51). Of course, we can-
not overlook the impact of the chosen antihypertensive 
regimen on kidney responses, as it is known from ACE 
inhibitors benefits towards glomerular function and 
their enhanced efficacy when associated with diuretics 
and calcium channel blockers.
Albuminuria responses through decreased BP were 
significant and similar when both obese hypertensive 
subgroups were considered and the benefits achieved 
were even greater for troncular obese patients, consid-
ering their pretreatment albuminuria level ranges.
In the light of these results, requirements of narrower 
target BP levels in obese individuals, similarly to those of 
diabetic patients, may be required in view of the poten-
tially greater renal damage in this population, especially 
the visceral obese people, whose renal hemodynamics 
seem to be particularly impaired (4).
These results denoted that target organ responses, 
upon blood pressure control, do not occur necessarily in 
a parallel fashion, which reinforces the importance of 
controlling each organ response separately and normal-
izing other risk factors. This concurs with the current 
concept that antihypertensive treatment should be titrat-
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ed to blood pressure reduction and also to target organ 
protection (52), which may be evaluated previously and 
during antihypertensive treatment, especially in high risk 
groups, in order to achieve a global cardiovascular risk 
reduction.
In conclusion, our study showed that treatment of 
hypertensive obese women, in the absence of appropri-
ate weight loss, required mostly an antihypertensive drug 
combination, and this requirement was not mediated by 
the type of obesity to achieve the same antihypertensive 
efficacy. Troncular obese patients experienced an even 
greater decrease in previously exacerbated nocturnal 
blood pressures. The achievement of a satisfactory BP 
range was also accompanied by microalbuminuria nor-
malization, which was also similar in both obese sub-
groups. Despite the antihypertensive effectiveness, the 
benefits of BP control to cardiac structure were less evi-
dent and probably lesser due to the weight maintenance, 
especially in the troncular obese subjects, in which the 
left ventricle has remained hypertrophic.
Limitations of our study are the relative small sam-
ple size and the absence of men in the study. Further 
studies with a larger population, focusing on heteroge-
neous groups of obese subjects and seeking “ideal” an-
tihypertensive combination therapies along with weight 
reduction programs and/or measures to revert visceral 
adiposity deposition, are required to establish thera-
peutic guidelines for this population.
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